Extended follow-up demonstrated reduced mortality risk with pTVG-HP plus GM-CSF versus GM-CSF alone (median OS 13.4 vs 8.6 years; ~58% risk reduction). Two-year primary metastasis-related endpoints ...
A Louisiana-based biopharmaceutical company is betting that its experimental immunotherapeutic vaccine can keep previously untreated prostate cancer in check. The company, OncBioMune Pharnaceuticals, ...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
Sowing the Soil for Cure? Results of the ABCSG-12 Trial Open a New Chapter in the Evolving Adjuvant Bisphosphonate Story in Early Breast Cancer Prostatic acid phosphatase (PAP) is a prostate tumor ...
The rapid clinical validation of mRNA technology during the COVID‑19 pandemic has powerfully accelerated its application in oncology, and this comprehensive review provides a state‑of‑the‑art ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results